AprilBio, a KOSDAQ-listed company, announced on February 24th a planned private placement to raise approximately 142 billion Korean won (roughly $108 million USD). The funds will be used for operational capital and to bolster the company’s business ventures. The investment will be made through a third-party allocation of shares. This move aims to strengthen AprilBio’s financial standing and support future growth initiatives. Details regarding the specific investors involved in the placement were not immediately disclosed. The company expects the capital injection to facilitate expansion and innovation within its biotechnology operations. This fundraising round signals continued investor confidence in AprilBio’s potential.